Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768309 | 1.00 | SLC22A1 (0.42) | SLC22A1PRCPHTR6HTR2AHDAC8 | |
| SCHEMBL29768307 | 0.78 | RET (0.39) | HTR6HTR2ASIGMAR1RETCYP3A4 | |
| SCHEMBL28774778 | 0.78 | RET (0.39) | HTR6HTR2ASIGMAR1RETCYP3A4 | |
| SCHEMBL9138411 | 0.76 | EGFR (0.40) | HTR2AGAARETCYP1A2 | |
| SCHEMBL9595697 | 0.74 | ALDH1A1 (0.39) | HTR2AGAARET | |
| Hydrochloric Acid SCHEMBL7600781 | 0.72 | HTR2A (0.34) | HTR2ARET | |
| SCHEMBL7759088 | 0.71 | HTR2A (0.37) | HTR2ARETCYP3A4 | |
| SCHEMBL30149414 | 0.69 | HTR2A (0.32) | HTR2ACYP1A2CYP2C19 | |
| SCHEMBL1027583 | 0.68 | HTR6 (0.74) | SLC22A1PRCPHTR6HTR2AHDAC8 | |
| SCHEMBL22345616 | 0.68 | PRCP (0.43) | PRCPHTR2ASIGMAR1GAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671807-A | Preparation method of 1-substituted isoquinoline compound | 联化科技（德州）有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2006-12-21 | — | — | US | disclosed |
| EP-1613635-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004073598-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A.U. (ES) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | TSNAX, TSN, PLIN5 | SLC22A1 3507/4885PRCP 1589/4885HTR6 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.